Bankole Johnson, MD and Chairman of the Board of Adial Pharmaceuticals Featured in Second Installment of The Doctors Channel ...
January 15 2019 - 9:05AM
Adial Pharmaceuticals, Inc.
(NASDAQ:ADIL), www.adialpharma.com, a clinical-stage
biopharmaceutical company focused on the development of medicines
for addiction, today announced that Bankole Johnson, MD, the
Company’s Chairman of the Board, was featured in a second video
produced by The Doctors Channel discussing the Company’s lead asset
AD04 alcohol use disorder (AUD) drug about to begin Phase 3
clinical trials. The most recent video can be viewed at:
https://www.thedoctorschannel.com/view/pharmacogenetic-approach-to-treating-alcohol-use-disorder/.
The first video was made available in November
2018 and can be viewed at:
https://www.thedoctorschannel.com/view/alcohol-use-disorders-exact-massive-global-health-toll/
The Doctors Channel is the world’s largest video
site for doctors featuring short-form accredited CME, medical news
and lifestyle videos. The Doctor’s Channel reports over 450,000
physicians and clinicians in-network and has a growing video
library consisting of more than 6,500 videos.
Dr. Johnson is a renowned addiction expert and
currently holds a number of titles including the Dr. Irving J.
Taylor Professor and Chair, Department of Psychiatry, University of
Maryland. He has written and spoken extensively about Alcohol Use
Disorder (AUD) and is regularly sought by authorities around the
world for his expertise in the sector.
“Sharing what I’ve learned and my conclusions
about alcohol use disorder through The Doctors Channel with the
many experts who are on the frontlines of the addiction battle is
both humbling and productive as together we can share best
practices and keep our collective efforts in the public eye,” said
Dr. Johnson. “Our goal is to save lives and reduce the pain,
suffering and loss of productivity associated with all addictions.
Shared information through such respected channels will help give
our efforts that much more impact.”
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage
biopharmaceutical company focused on the development of treatments
for addictions. The Company’s lead investigational new drug
product, AD04, is a genetically targeted therapeutic agent for the
treatment of alcohol use disorder (“AUD”). A Phase 2b clinical
trial of AD04 for the treatment of AUD showed promising results in
reducing frequency of drinking, quantity of drinking and heavy
drinking (all with statistical significance), and no overt safety
concerns (there were no statistically significant serious adverse
events reported). The Company plans to commence a Phase 3 clinical
trial using AD04 for the potential treatment of AUD in subjects
with certain target genotypes, which are to be identified using the
Company’s proprietary companion diagnostic genetic test. AD04 is
also believed to have the potential to treat other addictive
disorders such as opioid use disorder, gambling, and obesity.
Forward Looking Statements
This communication contains certain
“forward-looking statements” within the meaning of the U.S. federal
securities laws. Such statements are based upon various facts and
derived utilizing numerous important assumptions and are subject to
known and unknown risks, uncertainties and other factors that may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. The forward-looking statements include commencement
of the planned phase 3 clinical trial using AD04 for the potential
treatment of AUD in subjects with certain genotypes, the potential
of AD04 to treat AUD and other addictive disorders and the ability
of AD04 to save lives, reduce pain, suffering and loss of
productivity associated with addictions. Any forward-looking
statements included herein reflect our current views, and they
involve certain risks and uncertainties, including, among others,
the ability commence the Phase 3 clinical trials in the first half
of 2019, the ability to expand the use of AD04 for use in patients
with opioid use disorder, the ability
of AD04 therapy to perform as designed, to demonstrate
safety and efficacy, as well as results that are consistent with
prior results, the ability to enroll patients and complete the
clinical trials on time and achieve desired results and benefits,
our ability to obtain regulatory approvals for commercialization of
product candidates or to comply with ongoing regulatory
requirements, regulatory limitations relating to our ability
to promote or commercialize our product candidates for specific
indications, acceptance of its product candidates in the
marketplace and the successful development, marketing or sale of
products, our ability to maintain our license agreements, the
continued maintenance and growth of our patent estate, our ability
to establish and maintain collaborations, our ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities, and our ability to retain our key employees
or maintain our Nasdaq listing. These risks should not be construed
as exhaustive and should be read together with the other cautionary
statement included in our registration statement on Form S-1 that
we have filed with the SEC and the final prospectus and our Current
Report on Form 10-Q for the quarter ended September 30, 2018. Any
forward-looking statement speaks only as of the date on which it
was initially made. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events, changed circumstances or otherwise,
unless required by law.
Media:
Black Dog Communications Group, Inc. Shep Doniger Tel:
561-637-5750 Email: sdoniger@bdcginc.com
Investors:Crescendo Communications, LLC David
Waldman Tel: 212-671-1021 Email: ADIL@crescendo-ir.com
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Apr 2023 to Apr 2024